RU2006102955A - Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов - Google Patents
Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов Download PDFInfo
- Publication number
- RU2006102955A RU2006102955A RU2006102955/04A RU2006102955A RU2006102955A RU 2006102955 A RU2006102955 A RU 2006102955A RU 2006102955/04 A RU2006102955/04 A RU 2006102955/04A RU 2006102955 A RU2006102955 A RU 2006102955A RU 2006102955 A RU2006102955 A RU 2006102955A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- ring
- hydrogen atom
- phenyl
- ethyl
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 88
- 150000001875 compounds Chemical class 0.000 claims 76
- -1 NRSO 2 Inorganic materials 0.000 claims 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 69
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 62
- 229910052760 oxygen Inorganic materials 0.000 claims 62
- 125000001931 aliphatic group Chemical group 0.000 claims 61
- 125000005842 heteroatom Chemical group 0.000 claims 44
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 42
- 229910052757 nitrogen Inorganic materials 0.000 claims 40
- 125000003118 aryl group Chemical group 0.000 claims 38
- 239000001301 oxygen Chemical group 0.000 claims 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 35
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 32
- 125000005843 halogen group Chemical group 0.000 claims 31
- 229910052717 sulfur Inorganic materials 0.000 claims 29
- 125000004429 atom Chemical group 0.000 claims 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 27
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 25
- 125000004434 sulfur atom Chemical group 0.000 claims 24
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 23
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000004432 carbon atom Chemical group C* 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 11
- 229920006395 saturated elastomer Polymers 0.000 claims 11
- 239000011593 sulfur Substances 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 10
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 9
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 9
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 8
- 125000003386 piperidinyl group Chemical group 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 7
- 125000004193 piperazinyl group Chemical group 0.000 claims 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000005505 thiomorpholino group Chemical group 0.000 claims 5
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000005936 piperidyl group Chemical group 0.000 claims 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 2
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical group C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000009172 bursting Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 206010061928 radiculitis Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436203P | 2003-07-02 | 2003-07-02 | |
| US60/484,362 | 2003-07-02 | ||
| US50020003P | 2003-09-04 | 2003-09-04 | |
| US60/500,200 | 2003-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006102955A true RU2006102955A (ru) | 2007-08-20 |
Family
ID=33567720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006102955/04A RU2006102955A (ru) | 2003-07-02 | 2004-07-02 | Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7816529B2 (enExample) |
| EP (1) | EP1638955A2 (enExample) |
| JP (1) | JP2007521287A (enExample) |
| KR (1) | KR20060032190A (enExample) |
| AR (1) | AR045010A1 (enExample) |
| AU (1) | AU2004253962A1 (enExample) |
| CA (1) | CA2531061A1 (enExample) |
| IL (1) | IL172937A0 (enExample) |
| MX (1) | MXPA06000051A (enExample) |
| NO (1) | NO20060518L (enExample) |
| PE (1) | PE20051029A1 (enExample) |
| RU (1) | RU2006102955A (enExample) |
| TW (1) | TW200519094A (enExample) |
| WO (1) | WO2005003099A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2533115C2 (ru) * | 2009-02-03 | 2014-11-20 | Оцука Фармасьютикал Ко., Лтд. | Новое цианопиримидиновое производное |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06000051A (es) * | 2003-07-02 | 2006-03-21 | Vertex Pharma | Pirimidinas utiles como moduladores de canales ionicos dependientes de voltaje. |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| EP1863796A1 (en) * | 2005-03-22 | 2007-12-12 | NeuroSearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
| EP1877381A1 (en) * | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| US7858786B2 (en) * | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
| EP1904491A2 (en) * | 2005-05-31 | 2008-04-02 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
| AU2007245496A1 (en) | 2006-04-26 | 2007-11-08 | Cancer Research Technology Limited | Amino-ethyl-amino-aryl (AEAA) compounds and their use |
| JP2009539988A (ja) * | 2006-06-12 | 2009-11-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルの調節因子として有用なチエノピリミジン |
| WO2008104869A1 (en) | 2007-02-26 | 2008-09-04 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| WO2008110891A2 (en) * | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| DK2465541T3 (en) | 2007-05-22 | 2018-09-17 | Wyeth Llc | improved methods for producing hydrazides |
| JP2009007273A (ja) * | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | ジアミノピリミジン化合物の製造方法 |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| ES2445444T3 (es) * | 2007-10-11 | 2014-03-03 | Glaxosmithkline Llc | Nuevos inhibidores de sEH y su uso |
| DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
| WO2009097476A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| JP2011510996A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| JP2011510997A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| US20090198057A1 (en) * | 2008-02-05 | 2009-08-06 | Pu-Ping Lu | Certain Chemical Entities, Compositions, and Methods |
| WO2010033977A2 (en) | 2008-09-22 | 2010-03-25 | Cayman Chemical Company | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| EA026132B1 (ru) * | 2010-09-13 | 2017-03-31 | Новартис Аг | Триазиноксадиазолы, фармацевтические композиции на их основе и их применение |
| US9199962B2 (en) * | 2011-07-07 | 2015-12-01 | Merck Patent Gmbh | Substituted azaheterocycles for the treatment of cancer |
| EP3268360B1 (en) | 2015-03-09 | 2019-04-24 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| GB201721751D0 (en) * | 2017-12-22 | 2018-02-07 | Adorx Therapeutics Ltd | Compounds |
| EP4320103A1 (en) * | 2021-04-09 | 2024-02-14 | Quanta Therapeutics, Inc. | Pyrimidine based ras modulators and uses thereof |
| TW202339734A (zh) | 2021-12-23 | 2023-10-16 | 比利時魯汶大學 | 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之２－吡唑苯胺及相關類似物 |
| IL314812A (en) | 2022-02-09 | 2024-10-01 | Quanta Therapeutics Inc | Kras modulators and uses thereof |
| CN119604501A (zh) | 2022-05-25 | 2025-03-11 | 光达治疗公司 | 基于嘧啶的调节剂及其用途 |
| WO2024192424A1 (en) | 2023-03-15 | 2024-09-19 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB901749A (en) * | 1957-12-06 | 1962-07-25 | Ciba Ltd | New 2-substituted pyrimidines |
| US3040047A (en) * | 1960-04-04 | 1962-06-19 | Takeda Pharmaceutical | 2-(pyrazol-1-yl)-pyrimidine derivatives |
| US3850928A (en) * | 1969-11-04 | 1974-11-26 | American Home Prod | Substituted 6-alkylamino-2-phenyl-5-pyrimidine carboxylic acids |
| US3850931A (en) * | 1971-06-25 | 1974-11-26 | American Home Prod | 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters |
| US3759922A (en) * | 1971-06-25 | 1973-09-18 | American Home Prod | Preparation of pyrimido(5,4-c)(1,5) benz oxazepin-5(11h)-ones and intermediates |
| US3860596A (en) * | 1972-08-31 | 1975-01-14 | American Home Prod | 2-aryl-4-substituted-amino-5-pyrimidyl derivatives |
| DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| FR2263750A1 (en) | 1974-03-12 | 1975-10-10 | Delalande Sa | N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc. |
| FR2281117A2 (fr) * | 1974-08-09 | 1976-03-05 | Ugine Kuhlmann | Nouvelles piperazino-pyrimidines utilisables comme medicaments |
| JPS6044303B2 (ja) * | 1975-02-25 | 1985-10-02 | 大日本製薬株式会社 | ２−環状アミノ−４−アミノピリミジン誘導体の製造法 |
| WO1987004928A1 (fr) | 1986-02-24 | 1987-08-27 | Mitsui Petrochemical Industries, Ltd. | Agents therapeutiques de la neuropathie |
| HUP0303841A2 (hu) * | 2001-02-20 | 2004-03-01 | Bristol-Myers Squibb Company | 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk |
| US20040038856A1 (en) * | 2002-05-17 | 2004-02-26 | Sarvajit Chakravarty | Treatment of fibroproliferative disorders using TGF-beta inhibitors |
| MXPA06000051A (es) * | 2003-07-02 | 2006-03-21 | Vertex Pharma | Pirimidinas utiles como moduladores de canales ionicos dependientes de voltaje. |
| US7858786B2 (en) * | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
-
2004
- 2004-07-02 MX MXPA06000051A patent/MXPA06000051A/es unknown
- 2004-07-02 CA CA002531061A patent/CA2531061A1/en not_active Abandoned
- 2004-07-02 WO PCT/US2004/021440 patent/WO2005003099A2/en not_active Ceased
- 2004-07-02 AR ARP040102352A patent/AR045010A1/es unknown
- 2004-07-02 EP EP04777512A patent/EP1638955A2/en not_active Withdrawn
- 2004-07-02 TW TW093120064A patent/TW200519094A/zh unknown
- 2004-07-02 PE PE20050002102004000638A patent/PE20051029A1/es not_active Application Discontinuation
- 2004-07-02 AU AU2004253962A patent/AU2004253962A1/en not_active Abandoned
- 2004-07-02 RU RU2006102955/04A patent/RU2006102955A/ru not_active Application Discontinuation
- 2004-07-02 US US10/884,865 patent/US7816529B2/en not_active Expired - Fee Related
- 2004-07-02 KR KR1020067000095A patent/KR20060032190A/ko not_active Ceased
- 2004-07-02 JP JP2006517847A patent/JP2007521287A/ja not_active Withdrawn
-
2006
- 2006-01-02 IL IL172937A patent/IL172937A0/en unknown
- 2006-02-01 NO NO20060518A patent/NO20060518L/no not_active Application Discontinuation
-
2010
- 2010-09-08 US US12/877,793 patent/US8324220B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2533115C2 (ru) * | 2009-02-03 | 2014-11-20 | Оцука Фармасьютикал Ко., Лтд. | Новое цианопиримидиновое производное |
| US9708292B2 (en) | 2009-02-03 | 2017-07-18 | Otsuka Pharmaceutical Co., Ltd. | Cyanopyrimidine derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| US7816529B2 (en) | 2010-10-19 |
| US20110003814A1 (en) | 2011-01-06 |
| IL172937A0 (en) | 2006-06-11 |
| NO20060518L (no) | 2006-03-07 |
| PE20051029A1 (es) | 2005-12-07 |
| WO2005003099A2 (en) | 2005-01-13 |
| WO2005003099A3 (en) | 2005-05-12 |
| KR20060032190A (ko) | 2006-04-14 |
| MXPA06000051A (es) | 2006-03-21 |
| EP1638955A2 (en) | 2006-03-29 |
| CA2531061A1 (en) | 2005-01-13 |
| AR045010A1 (es) | 2005-10-12 |
| US8324220B2 (en) | 2012-12-04 |
| TW200519094A (en) | 2005-06-16 |
| JP2007521287A (ja) | 2007-08-02 |
| AU2004253962A1 (en) | 2005-01-13 |
| US20050049247A1 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006102955A (ru) | Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов | |
| JP2007521287A5 (enExample) | ||
| ES2655899T3 (es) | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de la Trk cinasa | |
| KR101784798B1 (ko) | ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５ａ］ 피리미딘 화합물 | |
| RU2745035C1 (ru) | Ингибитор fgfr и его применение | |
| KR101974254B1 (ko) | Fgfr 저해제의 간헐 투여용 항종양제 | |
| RU2441006C2 (ru) | 4, 5-ДИГИДРО-[1, 2, 4]ТРИАЗОЛО[4, 3-F]ПТЕРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ Plk1 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| CN114025755B (zh) | 以杂环化合物作为激酶抑制剂的治疗用途 | |
| HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
| RU2006106710A (ru) | Конденсированные пиримидиновые соединения в качестве ингибиторов потенциалозависимых ионных каналов | |
| RU2014154397A (ru) | Соединения тетрагидропиразолопиримидина | |
| HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
| KR20090014219A (ko) | 피롤로피리미딘 화합물 및 그의 용도 | |
| RU2018131539A (ru) | Соединение мочевины, способ его получения и его медицинское применение | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| AU2006229995A1 (en) | Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives | |
| CA2724215C (en) | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | |
| ES2384509T3 (es) | Heteroarilpirrolopiridinonas activas como inhibidoras de cinasas | |
| AU2021323844A1 (en) | FGFR and mutation inhibitor thereof, preparation method therefor and use thereof | |
| AU2022249724B2 (en) | Pharmaceutical compound | |
| CA3136468C (en) | Pyrazolopyrazine derived compounds and pharmaceutical compositions used as jak inhibitors | |
| HK40061639B (zh) | 以杂环化合物作为激酶抑制剂的治疗用途 | |
| HK40061639A (en) | Heterocyclic compounds as kinase inhibitors for therapeutic uses | |
| RU2021110751A (ru) | Противовирусные средства для лечения и профилактики вич-инфекции | |
| RU2020107455A (ru) | Противовирусные средства для лечения и профилактики вич инфекции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100202 |